EQUENCE LISTING 20 Rec'd PCT/PTO 06 JUN 2006

```
Imperial College Innovations Limited
<110>
        Therapeutically Useful Molecules
<120>
<130>
        28646/42100
        PCT/GB2004/005100
<140>
<141>
        2004-12-06
<150>
        GB 0328363.7
<151>
        2003-12-06
<160>
<170>
        SeqWin99
<210>
        1
<211>
        9
<212>
        PRT
<213>
        Artificial Sequence
<220>
        Peptide of WT1 which is presented by HLA-A2 class I molecules
<223>
Arg Met Phe Pro Asn Ala Pro Tyr Leu
<210>
        2
<211>
        6
<212>
        PRT
<213>
        Artificial Sequence
<220>
        CDR1 of human TCR V -1.5 (V -8.2)
<223>
<400>
Ser Ser Tyr Ser Pro Ser
                 5
<210>
<211>
        7
<212>
        PRT
<213>
        Artificial Sequence
<220>
        CDR2 of human TCR V -1.5 (V -8.2)
<223>
<400>
        3
Tyr Thr Ser Ala Ala Thr Leu
                 5
<210>
        4
<211>
        14
<212>
        PRT
<213>
        Artificial Sequence
<220>
        CDR3 of human TCR V -1.5 (V -8.2) -1
<223>
```

```
<400>
Val Val Ser Pro Phe Ser Gly Gly Gly Ala Asp Gly Leu Thr
<210>
        5
<211>
        12
<212>
       PRT
<213>
       Artificial Sequence
<220>
      CDR3 of human TCR V -1.5 (V -8.2) - 2
<223>
Ser Pro Phe Ser Gly Gly Gly Ala Asp Gly Leu Thr
<210>
        6
<211>
        6
<212>
        PRT
<213>
        Artificial Sequence
<220>
        CDR1 of human TCR V -2.1 (V -20.1)
<223>
<400>
Asp Phe Gln Ala Thr Thr
<210>
<211>
        7
<212>
       PRT
       Artificial Sequence
<213>
<220>
       CDR2 of human TCR V -2.1 (V -20.1)
<223>
<400>
Ser Asn Glu Gly Ser Lys Ala
           <sub>.</sub> 5
<210>
<211>
        8
<212>
       PRT
<213>
       Artificial Sequence
<220>
       CDR3 of human TCR V -2.1 (V -20.1) - 1
<223>
Ser Ala Arg Asp Gly Gly Glu Gly
<210>
        9
<211>
        11
<212>
       PRT
       Artificial Sequence
<213>
<220>
<223>
       CDR3 of human TCR V -2.1 (V -20.1) - 2
<400>
Arg Asp Gly Gly Glu Gly Ser Glu Thr Gln Tyr
```

```
<210>
        10
<211>
        11
<212>
        PRT
        Artificial Sequence
<213>
<220>
<223> Framework amino acid sequence of constant portion C-terminal to
CDR3
<400>
Phe Gly Lys Gly Thr His Leu Ile Ile Gln Pro
<210>
        11
<211>
        5
<212>
        PRT
<213>
        Artificial Sequence
<220>
<223>
        Beginning of constant region of human TCR V -1.5 (V -8.2)
<400>
        11
Tyr Ile Gln Asn Pro
<210>
        12
<211>
        5
<212>
        PRT
<213>
        Artificial Sequence
<220>
        Beginning of framework amino acid sequence of human TCR V -2.1\ (V^{:}
<223>
-20.1)
<400>
        12
Ser Glu Thr Gln Tyr
<210>
        13
<211>
        10
<212>
        PRT
<213>
        Artificial Sequence
<220>
<223>
        Part of framework amino acid sequence of human TCR V -2.1 (V -20.1)
<400>
Phe Gly Pro Gly Thr Arg Leu Leu Val Leu
<210>
        14
<211>
        5
<212>
        PRT
        Artificial Sequence
<213>
<220>
<223>
        Part of constant region of human TCR V -2.1 (V -20.1)
<400>
        14
Glu Asp Leu Lys Asn
<210>
        15
```

```
<211>
        830
<212>
        DNA
<213>
        Human TCR V -1.5 (V -8.2)
<400>
        15
atgeteetge tgetegteec agtgetegag gtgattttta etetgggagg aaccagagee
cagteggtga eccagettga cagecaegte tetgtetetg aaggaaeeee ggtgetgetg
aggtgcaact actcatcttc ttattcacca tctctcttct ggtatgtgca acaccccaac
aaaggactcc agcttctcct gaagtacaca tcagcggcca ccctggttaa aggcatcaac
ggttttgagg ctgaatttaa gaagagtgaa acctccttcc acctgacgaa accctcagcc
catatgagcg acgcggctga gtacttctgt gttgtgagtc ctttttcagg aggaggtgct
gacggactca cctttggcaa agggactcat ctaatcatcc agccctatat ccagaaccct
gaccetgeeg tgtaccaget gagagactet aaatecagtg acaagtetgt etgeetatte
accgattttg attctcaaac aaatgtgtca caaagtaagg attctgatgt gtatatcaca
gacaaaactg tgctagacat gaggtctatg gacttcaaga gcaacagtgc tgtggcctgg
agcaacaaat ctgactttgc atgtgcaaac gccttcaaca acagcattat tccagaagac
accttettee ceageceaga aagtteetgt gatgteaage tggtegagaa aagetttgaa
acagatacga acctaaactt tcaaaacctg tcagtgattg ggttccgaat cctcctcctg
aaagtggccg ggtttaatct gctcatgacg ctgcggctgt ggtccagctg
<210>
<211>
        276
<212>
        PRT
<213>
        Human TCR V -1.5 (V -8.2)
<400>
Met Leu Leu Leu Val Pro Val Leu Glu Val Ile Phe Thr Leu Gly
Gly Thr Arg Ala Gln Ser Val Thr Gln Leu Asp Ser His Val Ser Val
                                25
Ser Glu Gly Thr Pro Val Leu Leu Arg Cys Asn Tyr Ser Ser Syr Tyr
Ser Pro Ser Leu Phe Trp Tyr Val Gln His Pro Asn Lys Gly Leu Gln
Leu Leu Leu Lys Tyr Thr Ser Ala Ala Thr Leu Val Lys Gly Ile Asn
Gly Phe Glu Ala Glu Phe Lys Lys Ser Glu Thr Ser Phe His Leu Thr
Lys Pro Ser Ala His Met Ser Asp Ala Ala Glu Tyr Phe Cys Val Val
Ser Pro Phe Ser Gly Gly Gly Ala Asp Gly Leu Thr Phe Gly Lys Gly
Thr His Leu Ile Ile Gln Pro Tyr Ile Gln Asn Pro Asp Pro Ala Val
                        135
Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe
Thr Asp Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp
                165
                                    170
Val Tyr Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe
```

60

120

180

240

300

360

420

480

540

600

660

720

780

830

Lys Ser Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys

200 205 195 Ala Asn Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu 230 Thr Asp Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg 250 Ile Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg 265 Leu Trp Ser Ser 275 <210> 17 <211> 933 <212> DNA Human TCR V -2.1 (V -20.1) <213> <400> atgctgctgc ttctgctgct tctggggcca ggctccgggc ttggtgctgt cgtctctcaa 60 catccgagct gggttatctg taagagtgga acctctgtga agatcgagtg ccgttccctg 120 gactttcagg ccacaactat gttttggtat cgtcagttcc cgaaacagag tctcatgctg 180 atggcaactt ccaatgaggg ctccaaggcc acatacgagc aaggcgtcga gaaggacaag 240 tttctcatca accatgcaag cctgaccttg tccactctga cagtgaccag tgcccatcct 300 gaagacagca gcttctacat ctgcagtgct agagatgggg gggagggttc ggagacccag tactteggge caggeacgeg geteetggtg etegaggace tgaaaaacgt gtteecacee 420 480 gaggtcgctg tgtttgagcc atcagaagca gagatctccc acacccaaaa ggccacactg gtgtgcctgg ccacaggctt ctaccccgac cacgtggagc tgagctggtg ggtgaatggg 540 aaggaggtgc acagtggggt cagcacagac ccgcagcccc tcaaggagca gcccgccctc 600 aatgactcca gatactgcct gagcagccgc ctgagggtct cggccacctt ctggcagaac 660 ccccgcaacc acttccgctg tcaagtccag ttctacgggc tctcggagaa tgacgagtgg 720 acccaggata gggccaaacc tgtcacccag atcgtcagcg ccgaggcctg gggtagagca 780 gactgtggct tcacctccga gtcttaccag caaggggtcc tgtctgccac catcctctat 840 gagatettge tagggaagge cacettgtat geegtgetgg teagtgeect egtgetgatg 900 933 gccatggtca agagaaagga ttccagaggc tag <210> 18 <211> 310 <212> PRT Human TCR V -2.1 (V -20.1) <213> <400> Met Leu Leu Leu Leu Leu Gly Pro Gly Ser Gly Leu Gly Ala

Val Val Ser Gln His Pro Ser Trp Val Ile Cys Lys Ser Gly Thr Ser

Val Lys Ile Glu Cys Arg Ser Leu Asp Phe Gln Ala Thr Thr Met Phe

Trp Tyr Arg Gln Phe Pro Lys Gln Ser Leu Met Leu Met Ala Thr Ser

Asn Glu Gly Ser Lys Ala Thr Tyr Glu Gln Gly Val Glu Lys Asp Lys

Phe Leu Ile Asn His Ala Ser Leu Thr Leu Ser Thr Leu Thr Val Thr 90

Ser	Ala	His	Pro 100	Glu	Asp	Ser	Ser	Phe 105	Tyr	Ile	Cys	Ser	Ala 110	Arg	Asp		
Gly	Gly	Glu 115	Gly	Ser	Glu	Thr	Gln 120	Tyr	Phe	Gly	Pro	Gly 125	Thr	Arg	Leu		
Leu	Val 130	Leu	Glu	Asp	Leu	Lys 135	Asn	Val	Phe	Pro	Pro 140	Glu	Val	Ala	Val		
Phe 145	Glu	Pro	Ser	Glu	Ala 150	Glu	Ile	Ser	His	Thr 155	Gln	Lys	Ala	Thr	Leu 160		
Val	Cys	Leu	Ala	Thr 165	Gly	Phe	Tyr	Pro	Asp 170	His	Val	Glu	Leu	Ser 175	Trp		
Trp	Val	Asn	Gly 180	Lys	Glu	Val	His	Ser 185	Gly	Val	Ser	Thr	Asp 190	Pro	Gln		
Pro	Leu	Lys 195	Glu	Gln	Pro	Ala	Leu 200	Asn	Asp	Ser	Arg	Tyr 205	Cys	Leu	Ser		
Ser	Arg 210	Leu	Arg	Val	Ser	Ala 215	Thr	Phe	Trp	Gln	Asn 220	Pro	Arg	Asn	His		
Phe 225	Arg	Cys	Gln	Val	Gln 230	Phe	Tyr	Gly	Leu	Ser 235	Glu	Asn	Asp	Glu	Trp 240		
Thr	Gln	Asp	Arg	Ala 245	Lys	Pro	Val	Thr	Gln 250	Ile	Val	Ser	Ala	Glu 255	Ala		
Trp	Gly	Arg	Ala 260	Asp	Cys	Gly	Phe	Thr 265	Ser	Glu	Ser	Tyr	Gln 270	Gln	Gly		•
Val	Leu	Ser 275	Ala	Thr	Ile	Leu	Tyr 280	Glu	Ile	Leu	Leu	Gly 285	Lys	Åla	Thr		
Leu	Tyr 290	Ala	Val	Leu	Val	Ser 295	Ala	Leu	Val		Met 300	Ala	Met	Val	ГÀ̀з		
Arg 305	Lys	Asp	Ser	Arg	Gly 310												